Full text is available at the source.
Abstract
The management of type 2 diabetes mellitus (T2DM) in Romania is evolving toward integrated cardio-renal-metabolic protection.
- SGLT2 inhibitors and GLP-1 receptor agonists are associated with significant cardiovascular and renal benefits.
- Current outpatient care practices for T2DM may not fully implement these advanced treatments.
- There is a lack of characterization regarding the burden of persistent residual risk in Romanian patients with T2DM.
Simplified